author-photo

Ticiana A. Leal

University of Wisconsin-Madison

37

Papers

1857

Citations

Citation Trend

Filter By

Papers (28) Sort By

Journal Conference Others

1191O MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
The Global Impact of COVID-19 on Telehealth and Care for Persons With Thoracic Cancers

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (32)
Health-related quality of life for pembrolizumab (pembro) plus ipilimumab (ipi) versus pembro plus placebo in patients with metastatic NSCLC with PD-L1 tumor proportion score ≥ 50%: KEYNOTE-598.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021

2021 Journal of The National Comprehensive Cancer Network
Show All
- Source
- Cite
- Save
Citations (67)
ATR Inhibitor M6620 (VX-970) Enhances the Effect of Radiation in Non-Small Cell Lung Cancer Brain Metastasis Patient-Derived Xenografts.

2021 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
PS01.09 Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (36)
Prognostic performance of proteomic testing in advanced non-small cell lung cancer: a systematic literature review and meta-analysis.

2020 Current Medical Research and Opinion
Show All
- Source
- Cite
- Save
Citations (2)
Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial.

2020 Cancer Medicine
Show All
- Source
- Cite
- Save
Citations (0)